Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | CTRC | Q99895 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 4/20 | 0.51 |
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714701 | 0.82 | ELANE (0.51) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL21193209 | 0.81 | ELANE (0.53) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL1352319 | 0.81 | ELANE (0.59) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL290791 | 0.78 | POLB (0.70) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL8416125 | 0.78 | ELANE (0.55) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL16397249 | 0.76 | ELANE (0.53) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL2257976 | 0.75 | ELANE (0.61) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL2435976 | 0.75 | ELANE (0.51) | ELANEF2PLGCTSGCMA1 | |
| SCHEMBL40679 | 0.75 | POLB (0.61) | ELANEF2PLGCTSGCMA1 | |
| Bicarbonate SCHEMBL25171118 | 0.73 | POLB (0.64) | ELANEF2PLGCTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7514068-B2 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CONCERT PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007033366-A2 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CONCERT PHARMACEUTICALS INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258902-A1 | BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS | CNR2, CNR1, GPR119 | ELANE 1666/4885F2 1407/4885PLG 1179/4885 |
| US-20070276001-A1 | Biphenyl-pyrazolecarboxamide compounds | CNR2, CNR1, GPR119 | ELANE 1666/4885F2 1407/4885PLG 1179/4885 |
| US-20070066657-A1 | obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist | CNR2, CNR1, GPR119 | ELANE 2540/4885F2 1090/4885PLG 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.